Karen Taraszka Hastings

Dr. Karen Taraszka Hastings

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
EBElizabeth S. Borden
Elizabeth S. Borden
KBKenneth H. Buetow
Kenneth H. Buetow
MWMelissa A. Wilson
Melissa A. Wilson
KHKaren Taraszka Hastings
Karen Taraszka Hastings
Prioritization of immunogenic neoantigens is key to enhancing cancer immunotherapy through the development of personalized vaccines, adoptive T cell therapy, and the prediction of response to immune checkpoint inhibition. Neoantigens are tumor-specific proteins that allow the immune system to recognize and destroy a tumor. Cancer immunotherapies, such as personalized cancer vaccines, adoptive T cell therapy, and immune checkpoint inhibition, rely on an understanding of the patient-specific neoantigen profile in order to guide personalized therapeutic strategies. Genomic approaches to predicting and prioritizing immunogenic neoantigens are rapidly expanding, raising new opportunities to advance these tools and enhance their clinical relevance. Predicting neoantigens requires acquisition of high-quality samples and sequencing data, followed by variant calling and variant annotation. Subsequently, prioritizing which of these neoantigens may elicit a tumor-specific immune response requires application and integration of tools to predict the expression, processing, binding, and recognition potentials of the neoantigen. Finally, improvement of the computational tools is held in constant tension with the availability of datasets with validated immunogenic neoantigens. The goal of this review article is to summarize the current knowledge and limitations in neoantigen prediction, prioritization, and validation and propose future directions that will improve personalized cancer treatment.

1 December 2015 in Molecular Immunology
Verified
Journal Article
Closed access
MRMatthew P. Rausch
Matthew P. Rausch
KHKaren Taraszka Hastings
Karen Taraszka Hastings

1 September 2010 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
MRMatthew P. Rausch
Matthew P. Rausch
KIKari R. Irvine
Kari R. Irvine
PAPaul A Antony
Paul A Antony
NRNicholas P. Phillip Restifo
Nicholas P. Phillip Restifo
PCPeter Cresswell
Peter Cresswell
KHKaren Taraszka Hastings
Karen Taraszka Hastings
Melanocyte differentiation Ags, including tyrosinase-related protein (TRP) 1, are relevant to both autoimmune skin depigmentation (vitiligo) and tumor immunity, because they are expressed by both benign melanocytes and many malignant melanomas. Melanoma patients generate CD4+ T cells that specifically recognize these proteins. TRP1 contains internal disulfide bonds and is presented by MHC class II molecules. γ-IFN–inducible lysosomal thiol reductase (GILT) facilitates the generation of class II-binding peptides by the endocytic reduction of protein disulfide bonds. We show in this study that GILT is required for efficient MHC class II-restricted processing of a TRP1 epitope in vitro and accelerates the onset of vitiligo in TRP1-specific TCR transgenic mice. The presence of GILT confers a small increase in the percentage of autoreactive T cells with an effector memory phenotype that may contribute to earlier disease onset. The onset of vitiligo is associated with a greater increase in the percentage of autoreactive T cells with an effector memory phenotype. Given that many self and tumor Ags have disulfide bonds and are presented on MHC class II, GILT is likely to be important in the pathogenesis of other CD4+ T cell-mediated autoimmune diseases and for the development of effective cancer immunotherapy.

15 November 2019 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
KBKenneth H. Buetow
Kenneth H. Buetow
LMLydia R. Meador
Lydia R. Meador
HMHari Menon
Hari Menon
YLYih-Kuang Lu
Yih-Kuang Lu
JBJacob Brill
Jacob Brill
KHKaren Taraszka Hastings
Karen Taraszka Hastings
The MHC class I Ag presentation pathway in melanoma cells has a well-established role in immune-mediated destruction of tumors. However, the clinical significance of the MHC class II Ag presentation pathway in melanoma cells is less clear. In Ag-presenting cells, IFN-γ–inducible lysosomal thiol reductase (GILT) is critical for MHC class II–restricted presentation of multiple melanoma Ags. Although not expressed in benign melanocytes of nevi, GILT and MHC class II expression is induced in malignant melanocytes in a portion of melanoma specimens. Analysis of The Cancer Genome Atlas cutaneous melanoma data set showed that high GILT mRNA expression was associated with improved overall survival. Expression of IFN-γ, TNF-α, and IL-1β was positively associated with GILT expression in melanoma specimens. These cytokines were capable of inducing GILT expression in human melanoma cells in vitro. GILT protein expression in melanocytes was induced in halo nevi, which are nevi undergoing immune-mediated regression, and is consistent with the association of GILT expression with improved survival in melanoma. To explore potential mechanisms of GILT’s association with patient outcome, we investigated pathways related to GILT function and expression. In contrast to healthy skin specimens, in which the MHC class II pathway was nearly uniformly expressed and intact, there was substantial variation in the MHC class II pathway in the The Cancer Genome Atlas melanoma specimens. Both an active and intact MHC class II pathway were associated with improved overall survival in melanoma. These studies support a role for GILT and the MHC class II Ag presentation pathway in melanoma outcome.

1 January 2013 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
KHKaren Taraszka Hastings
Karen Taraszka Hastings
The MHC class II-restricted antigen processing pathway generates peptide:MHC complexes in the endocytic pathway for the activation of CD4+ T cells. Gamma-interferon-inducible lysosomal thiol reductase (GILT) reduces protein disulfide bonds in the endocytic compartment, thereby exposing buried epitopes for MHC class II binding and presentation. T cell hybridoma responses and elution of MHC class II bound peptides have identified GILT-dependent epitopes, GILT-independent epitopes, and epitopes that are more efficiently presented in the absence of GILT termed GILT-prevented epitopes. GILT-mediated alteration in the MHC class II-restricted peptidome modulates T cell development in the thymus and peripheral tolerance and influences the pathogenesis of autoimmunity. Recent studies suggest an emerging role for GILT in the response to pathogens and cancer survival.

30 April 2023 in Current Opinion in Immunology
Verified
Journal Article
Closed access
AMAnne M Macy
Anne M Macy
LHLauren M Herrmann
Lauren M Herrmann
AAAnngela C Adams
Anngela C Adams
KHKaren Taraszka Hastings
Karen Taraszka Hastings